Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (keynote-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Clinical implications of her2 mrna expression and intrinsic subtype in refractory her2-positive metastatic breast cancer treated with pan-her inhibitor, poziotinib.
Combined the smac mimetic and bcl2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-trna synthase-positive breast cancer.
Patient-reported outcomes of palbociclib plus exemestane with gnrh agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer: a prospective, open-label, randomized phase ll trial (kcsg-br 15-10).
